The delta variant has already become the dominant strain in the U.K. and is on its way to becoming the same in the U.S. That's troubling because the U.S. Centers for Disease Control and Prevention (CDC) has said the mutation is more contagious than other variants and causes more severe symptoms.
It already makes up 10% of all new cases in the U.S. That's up from just 6% in a week. Thankfully, the Pfizer vaccine holds its own against the mutation.
Hit me one more time
Albert Bourla, Pfizer's CEO, has said that his company tested its vaccine against the variants and
has them covered. That's true ... kind of. Analysis in the U.K. showed two doses of the company's vaccine still provided significant protection from the mutated virus.
That full regimen was 92% effective in preventing symptomatic COVID from the alpha mutation. It dropped to 79% effective against the delta variant. Although there have been no studies of the Moderna vaccine, the performance is expected to be the same, according to White House medical advisor Dr. Anthony Fauci.
The story isn't as rosy after one jab. In that period before the second dose does its magic, the effectiveness was a far less robust 33%. Previously, the CDC had said the first shot of either the Pfizer or Moderna vaccine was 80% effective at preventing COVID.
All told, it's establishing a trend of slightly waning efficacy with each subsequent variant. Still, almost 18 months removed from the original sequencing of the virus, Pfizer's (and theoretically Moderna's) vaccines continue to offer protection far greater than even the best year's flu vaccine.